Tim advises and represents clients in contentious IP matters across a wide range of technologies, especially complex disputes requiring multinational co-ordination.  

Tim advises on contentious matters across all IP rights, with a strong focus on patent litigation and strategy. He represents clients in cases before the English Courts, as well as in proceedings before the European Patent Office. He has very extensive experience of advising clients on the co-ordination of international patent litigation strategy including in the consumer products, pharmaceutical, medical devices and electronics fields, and of managing multinational litigation campaigns. Tim also advises on related issues arising from international technology standards, patent pools and licensing, as well as pharmaceutical regulatory issues and SPCs.

Tim’s strong scientific background allows him readily to understand complex technical issues. He has advised on patents and litigation strategy relating to a diverse range of technical subject matter, including consumer products embodying a wide range of technologies and the processes for their manufacture, pharmaceutical and biotechnology products and formulations, medical devices and associated consumables, telecommunications (both implementation patents and those declared essential to telecommunications standards), industrial processes and consumer electronics.

Tim also has experience of patent portfolio due diligence / FTO projects, contentious design right issues and trade mark infringement disputes. 

Tim regularly presents at conferences, workshops and international meetings on UK and European patent law and litigation strategy issues.

Tim joined Powell Gilbert as an associate when the firm was founded in 2007, and became a partner in 2012.

Key Cases

• DSM v Algal Omega 3 / Mara Renewables (algal omega-3 oil production)
• Otsuka v GW Pharma (royalty issues regarding cannabinoid epilepsy therapies)
• Philip Morris v Nicoventures / BAT (heat-not-burn tobacco)
• CommScope v SOLiD (digital distributed antenna systems) 
• Napp v Dr Reddy’s & Sandoz (buprenorphine transdermal patches & subsequent cross undertaking damages inquiry)
• Accord Healthcare v Research Corporation Technologies (anti-epileptics)
• Varian v Elekta (MRI / radiotherapy devices)
• Merck Sharp & Dohme v Royalty Pharma Collection Trust (DPP-IV inhibitors)
• Unwired Planet v Huawei & Others (telecommunications)
• Fresenius v Advanced Renal Technologies (dialysis fluids)
• Baxter v Fresenius (medical devices)
• Motorola Mobility v BT (digital TV)
• Microsoft v Motorola Mobility (smartphones)
• Corma v Hegler Plastik (extruded plastics)
• Fresenius v CareFusion (medical devices)
• Nuance v Vlingo (speech recognition)
• Philips & Others v Alba (MPEG-2 / FRAND licensing)
• Sandoz / ratiopharm v Napp (controlled release oxycodone formulations)
• Aveva v LTS (nicotine transdermal patches) 
• Tupperware v Lékué (silicone products)